Walder Wyss advised Dr. Wild & Co. on sale of Pharma business
Walder Wyss acted as legal counsel to Dr. Wild & Co., the Swiss family-owned pharmaceutical manufacturer, on the sale of its Pharma business, including its product portfolio in Vitamin D and other well-known products, to Verfora an affiliate of Galenica Group (SIX Swiss Exchange: GALE), at the end of May 2021.
On this transaction, the Walder Wyss the team was led by Robert von Rosen (partner, corporate/m&a, pictured) and further included Andreas Wildi (partner, life sciences), Pandora Kunz-Notter (managing associate, regulatory), Michelle Bruni (senior associate, tax), Michael Schmassmann (associate, competition) and Luca A. Sprecher (trainee, corporate/m&a).
As per the press release published by Dr. Wild & Co., they will focus exclusively on their oral care business, for which all core products are manufactured at its own factory in Muttenz, Switzerland. This focus will enable the company to leverage the growth potential in the oral care sector both in Switzerland and abroad.
